Infliximab, a monoclonal antibody directed against tumor necrosis factor α (TNF-α), is an efficacious treatment for both moderate to severe Crohn’s disease and ulcerative colitis.1,2 It is also the first Food and Drug Administration (FDA)-approved biologic for the management of IBD and remains a first-line treatment option.3,4. Here, TNF is linked to inflammatory bowel disease.